DOI: 10.1093/bjd/ljag261 ISSN: 0007-0963
Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year
Elaine C Siegfried, Eulalia Baselga, Marlies de Graaf, Eric L Simpson, Mark Boguniewicz, Carsten Flohr, Lawrence F Eichenfield, Amy S Paller, Michele Ramien, Xing-Hua Gao, Jiyoung Ahn, Korey Capozza, Yonghao Ma, Lauren Bates, Ana B RossiAs atopic dermatitis signs and symptoms wax and wane, assessing severity scores over time best captures sustained response to treatment. We report that the majority of pediatric patients (6 months to 17 years) had sustained improvements in skin lesions (Eczema Area and Severity Index ≤ 7), itch (SCORING Atopic Dermatitis pruritus Visual Analog Scale [SCORAD Pruritus VAS < 4]), and sleep loss (SCORAD sleep loss VAS < 4) over one year of treatment with dupilumab.